Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Financings Of The Fortnight Follows The Money Wherever It Goes

This article was originally published in The Pink Sheet Daily

Executive Summary

Are VCs looking beyond biopharma to put money into areas like health services and diagnostics? Plus updates on Castlight, Agile Therapeutics, Otonomy, and more.

You may also be interested in...

$100 Million Venture Round Will Enable Castlight To Branch Out Further

The health care cost transparency firm, which has raised $181 million to date, hopes to grow its commercialization team, add features to its service and expand its reach.

Contraceptive Patch Maker Agile Recapitalizes With $45 Million Venture Round

Agile said in 2008 its lead product was ready for Phase III trials. Those trials might start soon, now that the firm has found new backers.

Icahn Tries To Rain On Genzyme's Investor Day Parade With Proxy Seeking Termeer's Ouster

Genzyme CEO and Chairman Termeer highlighted investor day presentation with five-point plan for enhancing shareholder value, including $2 billion stock repurchase plan.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts